BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...the 505(b)(2) pathway. BC Staff OxyContin, oxycodone MyoKardia Inc. Purdue Pharma L.P. Cara Therapeutics InCarda Azitra Zosano Leaps...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...DEFTA Partners also participated. Former Allergan plc executive Thomas Reilly will fill a CFO position at Cara Therapeutics Inc....
...Richard Makara, Cara’s VP, head of accounting and comptroller, had been interim CFO. BC Staff insitro PureTech Kaleido Biosciences Arcus Biosciences Akouos Chiasma AZTherapies Cara Therapeutics...
BioCentury | Apr 21, 2020
Product Development

Cara’s pruritus therapy headed for submission after second Phase III readout

...said on a conference call Tuesday that the company will seek Priority Review from FDA. Cara Therapeutics Inc....
...$0.60 to $15.42. Targets KOR (OPRK1) - κ opioid receptor Paul Bonanos, Associate Editor Korsuva, difelikefalin (IV CR845) Cara Therapeutics Inc. Kappa...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...biosimilars of bevacizumab, denosumab and aflibercept from Boan. Cara down on Phase II pruritus data Cara Therapeutics Inc....
...Tumor-associated calcium signal transducer 2 BioCentury Staff Brii Biosciences Immunomedics Inc. Hanmi Pharmaceutical Co. Ltd. RAPT Therapeutics Inc. Luye Pharma Group Ltd. Cara Therapeutics Inc. Shandong...
BioCentury | Jul 25, 2019
Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

...consensus of a loss of $0.11 on $252.5 million. Cara raises $126.5M in upsized follow-on Cara Therapeutics Inc....
...III" ). Paul Bonanos, Associate Editor Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso (Other) Alkermes plc AstraZeneca plc Biocon Ltd. Cara Therapeutics Inc. Evelo...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...MCV4 Prevent meningitis infection from serotypes A, C, W135, and Y Submit Chinese NDA 2H19 Cara Therapeutics Inc....
BioCentury | May 30, 2019
Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

...indication in 2014. Cara pruritus therapy meets in first Phase III Korsuva (CR845/difelikefalin) Injection from Cara Therapeutics Inc....
..."Phase II Meet for Novartis Asthma Triplet" ). Brian Moy, Assistant Editor indacaterol/mometasone furoate (QMF149) Korsuva, difelikefalin (IV CR845) Cara Therapeutics Inc. CDC National...
BioCentury | May 23, 2019
Company News

With Merck veterans at the helm, Nektar launches subsidiary for pain compound

...Stauffer was principal and founder of Alta Life Sciences and CMO at multiple biopharmas including Cara Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Pharmaceutical Co. Ltd. (Tokyo:4559) Eflornithine/ sulindac Treat familial adenomatous polyposis (FAP) Phase III data 2Q19 Cara Therapeutics Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

.../ Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) Zydis rimegepant Prevent migraines Phase III data 2019 Cara Therapeutics Inc....
Items per page:
1 - 10 of 93
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...the 505(b)(2) pathway. BC Staff OxyContin, oxycodone MyoKardia Inc. Purdue Pharma L.P. Cara Therapeutics InCarda Azitra Zosano Leaps...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...DEFTA Partners also participated. Former Allergan plc executive Thomas Reilly will fill a CFO position at Cara Therapeutics Inc....
...Richard Makara, Cara’s VP, head of accounting and comptroller, had been interim CFO. BC Staff insitro PureTech Kaleido Biosciences Arcus Biosciences Akouos Chiasma AZTherapies Cara Therapeutics...
BioCentury | Apr 21, 2020
Product Development

Cara’s pruritus therapy headed for submission after second Phase III readout

...said on a conference call Tuesday that the company will seek Priority Review from FDA. Cara Therapeutics Inc....
...$0.60 to $15.42. Targets KOR (OPRK1) - κ opioid receptor Paul Bonanos, Associate Editor Korsuva, difelikefalin (IV CR845) Cara Therapeutics Inc. Kappa...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...biosimilars of bevacizumab, denosumab and aflibercept from Boan. Cara down on Phase II pruritus data Cara Therapeutics Inc....
...Tumor-associated calcium signal transducer 2 BioCentury Staff Brii Biosciences Immunomedics Inc. Hanmi Pharmaceutical Co. Ltd. RAPT Therapeutics Inc. Luye Pharma Group Ltd. Cara Therapeutics Inc. Shandong...
BioCentury | Jul 25, 2019
Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

...consensus of a loss of $0.11 on $252.5 million. Cara raises $126.5M in upsized follow-on Cara Therapeutics Inc....
...III" ). Paul Bonanos, Associate Editor Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso (Other) Alkermes plc AstraZeneca plc Biocon Ltd. Cara Therapeutics Inc. Evelo...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...MCV4 Prevent meningitis infection from serotypes A, C, W135, and Y Submit Chinese NDA 2H19 Cara Therapeutics Inc....
BioCentury | May 30, 2019
Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

...indication in 2014. Cara pruritus therapy meets in first Phase III Korsuva (CR845/difelikefalin) Injection from Cara Therapeutics Inc....
..."Phase II Meet for Novartis Asthma Triplet" ). Brian Moy, Assistant Editor indacaterol/mometasone furoate (QMF149) Korsuva, difelikefalin (IV CR845) Cara Therapeutics Inc. CDC National...
BioCentury | May 23, 2019
Company News

With Merck veterans at the helm, Nektar launches subsidiary for pain compound

...Stauffer was principal and founder of Alta Life Sciences and CMO at multiple biopharmas including Cara Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Pharmaceutical Co. Ltd. (Tokyo:4559) Eflornithine/ sulindac Treat familial adenomatous polyposis (FAP) Phase III data 2Q19 Cara Therapeutics Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

.../ Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) Zydis rimegepant Prevent migraines Phase III data 2019 Cara Therapeutics Inc....
Items per page:
1 - 10 of 93